This program is studying pravibismane, a new inhaled antibiotic. In the lungs of people with CF, bacteria may form protective layers -- known as biofilms -- that make them more difficult to kill. Pravibismane may help break down biofilms and kill drug-resistant bacteria, such as multi-drug resistant Pseudomonas aeruginosa and nontuberculous mycobacteria.
Laboratory studies to develop and test this compound are underway.
This program is sponsored by Microbion and partially funded by the Cystic Fibrosis Foundation.
Contact us about Microbion Biosciences >